Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00521118 · ClinicalTrials.gov registry record · Phase 2

Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors

A Phase 2 study, sponsored by Gynecologic Oncology Group.

Completed
Registry status
Phase 2
Development phase
64
Enrollment target

NCT00521118 is a Phase 2 study that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 64 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00521118, a Phase 2 study, has completed, sponsored by Gynecologic Oncology Group.

COMPLETED
Registry status
Phase 2
Development phase
64 participants
Enrollment target

Study Summary

This phase II trial studies how well a second curettage (removal of the abnormal cancer cells in the uterus using a method of surgically removing the lining of the uterus) works in treating patients with gestational trophoblastic tumors that did not go away after a first curettage (persistent) and has not yet spread to other places in the body (non-metastatic). A second curettage may be effective in treating persistent gestational trophoblastic tumors and may decrease the likelihood that patients will need chemotherapy in the near future.

Interventions

  • OTHER Laboratory Biomarker Analysis
  • PROCEDURE Therapeutic Conventional Surgery

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2007-10-09
Est. Completion 2015-06-25
Phase Phase 2

Sponsor

Gynecologic Oncology Group

154 total trials

What the Registry Record Tells You About NCT00521118

The ClinicalTrials.gov registry entry for NCT00521118 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.

NCT00521118 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00521118 about?

NCT00521118 is a clinical study titled "Second Curettage in Treating Patients With Persistent Non-metastatic Gestational Trophoblastic Tumors". This phase II trial studies how well a second curettage (removal of the abnormal cancer cells in the uterus using a method of surgically removing the lining of the uterus) works in treating patients with gestational trophoblastic tumors that did not go away after a first curettage (persistent) and h...

What is the current status of trial NCT00521118?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2007-10-09. Estimated completion is 2015-06-25.

What interventions are being tested in trial NCT00521118?

The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Therapeutic Conventional Surgery (PROCEDURE).

Who is sponsoring clinical trial NCT00521118?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.